Parliament Workbench
Data: Motions & questions to 26 Nov 2026

Written Question · S1W-24065 · Session 1

Further to the answer to question S1W-23111 by Malcolm Chisholm on 7 March 2002, whether there are any plans to ensure that the single meas…

Answered Asked by Mary Scanlon Con Lodged 13 Mar 2002

The question

To ask the Scottish Executive, further to the answer to question S1W-23111 by Malcolm Chisholm on 7 March 2002, whether there are any plans to ensure that the single measles vaccine is assessed by the UK Licensing Authority against the criteria of safety, quality and efficiency.

The answer

Answered by Malcolm Chisholm on 27 Mar 2002 · 14 days after it was lodged, on time

A full and formal assessment of product safety, quality and efficacy occurs in response to an application, by a pharmaceutical company, to the UK licensing authority for a marketing authorisation (product license). Marketing authorisations (product licenses) have been granted for single measles vaccine and these licenses are extant. The Medicines Control Agency is given more basic information about plans to import unlicensed medicinal products, such as unlicensed single measles vaccine. That notification is the subject of professional negative vetting for any evidence of quality or safety issues and whether there are any licensed equivalent products available on the market in the UK. The agency may object to importation if negative vetting raises any concerns.

In the Official Report

No contribution in the Official Report cites S1W-24065 by reference.